All In Biotech

Drug Trial Radar · NCT00483106

Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

Last checked: Nov 19, 2026Latest source record: Mar 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 885 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

885

Actual

Start

Nov 1999

Primary completion

Mar 31, 2020

Study completion Mar 31, 2020

Sponsor

Lead sponsor
McGill UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

  • RitalinDrug

    0.25 mg/kg bid, orally for 7 consecutive days

  • PlaceboDrug

    taken orally twice a day for 7 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Conners' Global Index - Parent Version (CGI-P)Time frame: Once weekly during the medication trial
  2. Conner's Global Index - Teacher Version (CGI-T)Time frame: Once weekly during the medication trial

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Douglas Mental Health University Institute

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.